Patients were prescribed Ozempic and other similar drugs for serious health problems

Multidistrict Litigation Filed Against Ozempic; cases are estimated at over 10,000

According to the Centers for Disease Control and Prevention, obesity rates have been rising steadily over the past few decades, with a staggering 41.2% of adults in the United States considered obese based on body mass index. This means that almost half of all adults in the US fall into the obese category.

In the face of growing obesity problems, pharmaceutical companies are actively promoting the effectiveness of Ozempic and other similar drugs that are very popular on the market. However, please remember that these medicines can only be obtained with a prescription. They were mainly used to treat type 2 diabetes by mimicking the effects of a hormone that helps regulate blood sugar levels. In addition, Ozempic and similar medications slow the rate at which food is emptied from the stomach, contributing to a feeling of fullness and reduced food intake.

These drugs – known as GLP-1 (glucagon-like peptide-1) receptor agonists – should only be used under medical supervision. They may cause side effects that make them unsuitable for everyone. Unfortunately, the manufacturers of Ozempic and other GLP-1 agonists did not adequately warn about the risks involved.

Currently, numerous lawsuits have been filed by people who took Ozempic and later suffered from gastroparesis, a serious condition that slows the flow of food through the stomach to the small intestine. In severe cases, this condition can cause stomach paralysis. Unfortunately, drug manufacturers have neglected to warn about this risk.

The first gastric paralysis lawsuit was filed on August 2, 2023. In February 2024, a multidistrict litigation (MDL) was filed against Ozempic in the Eastern District of Pennsylvania, including at least 55 lawsuits alleging that Ozempic and other GLP-Class 1 RA drugs caused severe damage to the digestive tract. It is estimated that the number of lawsuits may increase up to 10,000.

MDL is a legal process used in U.S. district courts to hear numerous civil cases across the country that have common issues of fact. The Ozempic MDL Group is made up of many plaintiffs from across the country who have experienced harmful side effects from Ozempic.

In September 2023, the FDA added intestinal blockage/obstruction and intestinal obstruction to the warning label for Ozempic.

At Robert Peirce & Associates, we understand the terrible consequences that people suffer from dangerous and defective drugs. Our dedicated team specializes in representing clients dealing with these types of matters.

Aaron Rihn is an attorney at Robert Peirce & Associates with extensive experience litigating class actions, pharmaceutical/device cases, civil rights cases, personal injury lawsuits, and professional liability cases. “Unfortunately, many people who have failed to achieve significant weight loss through lifestyle changes alone were told Ozempic was safe and had no idea that they could potentially suffer from gastroparesis – a dangerous and sometimes fatal disease,” she said. Rihn.

Other GLP-1 agonists named in claims such as Ozempic’s include:

• Wegovy

• Mounjaro

• Rybelsus

• Saxenda

• Veracity

• Related to the team

Symptoms of gastroparesis include nausea, vomiting, abdominal bloating, abdominal pain, severe dehydration, acid reflux, malnutrition, and weight loss. If you have been prescribed Ozempic for weight loss and have experienced any of these symptoms, contact the attorneys at Robert Peirce & Associates to see if you qualify for the Ozempic MDL program.

For over 40 years, Robert Peirce & Associates has provided supportive and compassionate legal representation to those injured by pharmaceutical company negligence. Contact Aaron Rihn of Robert Peirce & Associates for guidance and expert legal advice regarding your Ozempic MDL. Call today at 412-281-7229 or visit www.peircelaw.com.